邬晓臣, 岳琴, 王舰, 丁盛, 辛梅, 蒋利, 吴帆, 张近宝. 曲前列尼尔在高原地区先天性心脏病并发重度肺动脉高压围术期中的应用[J]. 心脏杂志, 2020, 32(6): 612-615. DOI: 10.12125/j.chj.202003012
    引用本文: 邬晓臣, 岳琴, 王舰, 丁盛, 辛梅, 蒋利, 吴帆, 张近宝. 曲前列尼尔在高原地区先天性心脏病并发重度肺动脉高压围术期中的应用[J]. 心脏杂志, 2020, 32(6): 612-615. DOI: 10.12125/j.chj.202003012
    Xiao-chen WU, Qin YUE, Jian WANG, Sheng DING, Mei XIN, Li JIANG, Fan WU, Jin-bao ZHANG. Application of treprostinil in patients with congenital heart disease and severe pulmonary arterial hypertension at plateau section[J]. Chinese Heart Journal, 2020, 32(6): 612-615. DOI: 10.12125/j.chj.202003012
    Citation: Xiao-chen WU, Qin YUE, Jian WANG, Sheng DING, Mei XIN, Li JIANG, Fan WU, Jin-bao ZHANG. Application of treprostinil in patients with congenital heart disease and severe pulmonary arterial hypertension at plateau section[J]. Chinese Heart Journal, 2020, 32(6): 612-615. DOI: 10.12125/j.chj.202003012

    曲前列尼尔在高原地区先天性心脏病并发重度肺动脉高压围术期中的应用

    Application of treprostinil in patients with congenital heart disease and severe pulmonary arterial hypertension at plateau section

    • 摘要:
        目的  探讨静脉持续注射曲前列尼尔在高原地区先天性心脏病(先心病)并发重度肺动脉高压(S-PAH)患儿围术期应用的安全性和有效性。
        方法  分别选择2015年1月~2016年10月和2017年1~-2018年10月入我院的高原地区先心病并S-PAH患儿各33例,前后两个住院时期的患儿按围术期是否使用曲前列尼尔分别设为试药组(33例,2017年1月~2018年10月入院)和对照组(33例,2015年1月~2016年10月入院)。对照组仅口服西地那非治疗,试药组在口服西地那非治疗的同时,给予曲前列尼尔静脉微泵注射给药至出院前,观察并评估每组患儿的一般临床指标、超声心动图、脑钠尿肽(BNP)等指标。
        结果  两组患儿一般临床指标和超声指标比较均无统计学意义,与入院时比较,两组患儿出院前肺动脉收缩压(PASP)和末梢氧饱和度明显下降,且试药组患儿PASP显著低于对照组(P<0.05),但末梢氧饱和度组间比较无显著差异;试药组患儿体外循环时间、呼吸机带管时间和ICU住院时间与对照组比较显著缩短(均P<0.05),两组患儿主动脉阻闭时间比较无明显差异;两组患儿出院前心排指数(CI)及BNP与术前比较差异显著(P<0.05),且出院前试药组BNP和CI与对照组比较有显著差异(均P<0.05),而左室射血分数两组比较差异不显著。
        结论  持续静脉注射曲前列尼尔在高原地区S-PAH患儿中能够安全、有效的控制PAH,减少患儿呼吸机带管时间和住院时间。

       

      Abstract:
        AIM  To investigate the safety and effectiveness of continuous intravenous injection of treprostinil in peri-operative period in treatment of pediatric congenital heart disease (CHD) with severe pulmonary arterial hypertension (S-PAH) at high altitude areas.
        METHODS  Thirty three children with CHD and S-PAH admitted to our hospital from January 2017 to October 2018 were selected as experimental group who were treated with treprostinilin in addition to regular oral sildenafil treatment, and other 33 patients admitted from January 2015 to October 2016 were selected as control group who were treated with only oral sildenafil and without treprostinil. Baseline data, echocardiography and BNP at admission and discharge were observed and evaluated in each group.
        RESULTS  There was no significant difference between the two groups in baseline data and ultrasonic indexes. The pulmonary artery systolic pressure (PASP) and peripheral oxygen saturation decreased significantly at the time of discharge in patients in both groups. The PASP in experimental group was significantly lower than that in control group (P<0.05), but there was no significant difference between the two groups in peripheral oxygen saturation. Compared with those in control group, the time of cardiopulmonary bypass, the time of ventilation and the time of ICU stay in experimental group were significantly lower (P<0.05), but no significant difference in the time of aortic occlusion was observed between the two groups. The difference of CI and BNP between the two groups at the time of discharge and operation was statistical significant (P<0.05). Moreover, the difference of BNP and CI between experimental group and control group was significant at the time of discharge, but there was no significant difference in EF value between the two groups.
        CONCLUSION  Continuous intravenous injection of treprostinil in CHD children with S-PAH at high altitude areas may control pulmonary arterial hypertension safely and effectively and effectively reduce the period of ventilation and hospitalization.

       

    /

    返回文章
    返回